Further predictive value of lymphovascular invasion explored via supervised deep learning for lymph node metastases in breast cancer.

Journal: Human pathology
Published Date:

Abstract

Lymphovascular invasion, specifically lymph-blood vessel invasion (LBVI), is a risk factor for metastases in breast invasive ductal carcinoma (IDC) and is routinely screened using hematoxylin-eosin histopathological images. However, routine reports only describe whether LBVI is present and does not provide other potential prognostic information of LBVI. This study aims to evaluate the clinical significance of LBVI in 685 IDC cases and explore the added predictive value of LBVI on lymph node metastases (LNM) via supervised deep learning (DL), an expert-experience embedded knowledge transfer learning (EEKT) model in 40 LBVI-positive cases signed by the routine report. Multivariate logistic regression and propensity score matching analysis demonstrated that LBVI (OR 4.203, 95% CI 2.809-6.290, P < 0.001) was a significant risk factor for LNM. Then, the EEKT model trained on 5780 image patches automatically segmented LBVI with a patch-wise Dice similarity coefficient of 0.930 in the test set and output counts, location, and morphometric features of the LBVIs. Some morphometric features were beneficial for further stratification within the 40 LBVI-positive cases. The results showed that LBVI in cases with LNM had a higher short-to-long side ratio of the minimum rectangle (MR) (0.686 vs. 0.480, P = 0.001), LBVI-to-MR area ratio (0.774 vs. 0.702, P = 0.002), and solidity (0.983 vs. 0.934, P = 0.029) compared to LBVI in cases without LNM. The results highlight the potential of DL to assist pathologists in quantifying LBVI and, more importantly, in exploring added prognostic information from LBVI.

Authors

  • Jiamei Chen
    Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Yang Yang
    Department of Gastrointestinal Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
  • Bo Luo
    School of mechanical science and engineering, Huazhong University of Science and Technology, Luoyu Road 1037, 430074, Wuhan, China.
  • Yaofeng Wen
  • Qingzhong Chen
    School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200000, China.
  • Ru Ma
    Department of Peritoneal Cancer Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China.
  • Zhen Huang
    Division of Medical Technology Development, Hangzhou Zhiwei Information & Technology Ltd., Hangzhou, Hangzhou, China.
  • Hangjia Zhu
    Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Yan Li
    Interdisciplinary Research Center for Biology and Chemistry, Liaoning Normal University, Dalian, China.
  • Yongshun Chen
    Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. Electronic address: cyszlsk@163.com.
  • Dahong Qian